Brokerages expect that Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) will report sales of $36.27 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Agios Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $33.40 million and the highest estimate coming in at $43.19 million. Agios Pharmaceuticals posted sales of $35.44 million in the same quarter last year, which suggests a positive year-over-year growth rate of 2.3%. The company is scheduled to announce its next quarterly earnings results on Thursday, February 11th.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $195.44 million for the current year, with estimates ranging from $192.60 million to $202.35 million. For the next year, analysts anticipate that the firm will post sales of $561.46 million, with estimates ranging from $78.00 million to $1.88 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($1.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.36) by ($0.07). The company had revenue of $34.70 million during the quarter, compared to analyst estimates of $38.12 million. Agios Pharmaceuticals had a negative net margin of 170.65% and a negative return on equity of 57.63%. The business’s quarterly revenue was up 33.5% compared to the same quarter last year. During the same period last year, the firm earned ($1.81) EPS.
Several brokerages have recently issued reports on AGIO. Barclays boosted their price objective on Agios Pharmaceuticals from $46.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 20th. Piper Sandler lifted their price target on Agios Pharmaceuticals from $73.00 to $80.00 in a research note on Monday, December 21st. Royal Bank of Canada cut their price target on Agios Pharmaceuticals from $59.00 to $66.00 in a research note on Tuesday, December 22nd. BidaskClub upgraded Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, December 28th. Finally, Cantor Fitzgerald lifted their price target on Agios Pharmaceuticals from $68.00 to $79.00 and gave the company an “overweight” rating in a research note on Thursday, November 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $63.92.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Amundi Pioneer Asset Management Inc. lifted its holdings in Agios Pharmaceuticals by 3,306.0% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 143,050 shares of the biopharmaceutical company’s stock valued at $9,648,000 after acquiring an additional 138,850 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Agios Pharmaceuticals by 35.3% during the second quarter. Principal Financial Group Inc. now owns 20,320 shares of the biopharmaceutical company’s stock worth $1,086,000 after purchasing an additional 5,302 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Agios Pharmaceuticals by 1,186.2% during the second quarter. PNC Financial Services Group Inc. now owns 1,672 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 1,542 shares in the last quarter. California Public Employees Retirement System lifted its stake in Agios Pharmaceuticals by 1.5% during the second quarter. California Public Employees Retirement System now owns 125,000 shares of the biopharmaceutical company’s stock worth $6,685,000 after purchasing an additional 1,900 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Agios Pharmaceuticals by 4.6% during the second quarter. Bank of New York Mellon Corp now owns 236,406 shares of the biopharmaceutical company’s stock worth $12,642,000 after purchasing an additional 10,395 shares in the last quarter. Hedge funds and other institutional investors own 79.99% of the company’s stock.
Shares of AGIO stock opened at $43.33 on Friday. The stock has a market cap of $3.00 billion, a PE ratio of -8.79 and a beta of 1.81. The business has a 50-day simple moving average of $41.24 and a 200-day simple moving average of $42.40. Agios Pharmaceuticals has a 52-week low of $27.77 and a 52-week high of $56.74.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.
See Also: Why investors pay attention to retained earnings
Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.